Brief: Immunocore Presents New Data On Cancer Treatment At Annual Oncology Conference
06/06/2022 12:09
June 6 (Reuters) - Immunocore Holdings PLC IMCR.O :
* IMMUNOCORE PRESENTS NEW DATA ON KIMMTRAK
(TEBENTAFUSP-TEBN) IN
METASTATIC CUTANEOUS (MCM) AND UVEAL MELANOMA (MUM) AT THE 2022
AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
* IMMUNOCORE HOLDINGS - TEBENTAFUSP AND ANTI-PDL1 SHOW 1
YEAR
OVERALL SURVIVAL OF ABOUT 75% IN HEAVILY PRE-TREATED MCM
COMPARED TO BENCHMARK OF 55%
* IMMUNOCORE HOLDINGS PLC - CORTICOSTEROID USE FOR TREATING
ADVERSE EVENTS OF T CELL ENGAGERS HAS NO SIGNIFICANT IMPACT ON
EFFICACY
Source text for Eikon: ID:nGNX75RfLH
Further company coverage: IMCR.O
((Reuters.Briefs@thomsonreuters.com;))